Patrys Limited (PAB.AX)
AUD 0.0
(0.0%)
AUD 0.0
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 1.39 Million AUD | -50.3% |
| 2023 | 2.8 Million AUD | -15.86% |
| 2022 | 3.33 Million AUD | 149.08% |
| 2021 | 1.33 Million AUD | 73.18% |
| 2020 | 772.84 Thousand AUD | -8.47% |
| 2019 | 844.36 Thousand AUD | 62.21% |
| 2018 | 520.52 Thousand AUD | -2.11% |
| 2017 | 531.72 Thousand AUD | -38.72% |
| 2016 | 867.65 Thousand AUD | -61.0% |
| 2015 | 2.22 Million AUD | 192.82% |
| 2014 | 759.68 Thousand AUD | 28643.21% |
| 2013 | 2643.00 AUD | -45.52% |
| 2012 | 4851.00 AUD | -36.16% |
| 2011 | 7599.00 AUD | 63.28% |
| 2010 | 4654.00 AUD | 24.61% |
| 2009 | 3735.00 AUD | 0.0% |
| 2008 | - AUD | 0.0% |
| 2007 | - AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 669.43 Thousand AUD | 0.0% |
| 2024 FY | -46.99 Thousand AUD | -101.68% |
| 2024 Q4 | 724.72 Thousand AUD | 0.0% |
| 2023 Q2 | 1.82 Million AUD | 0.0% |
| 2023 Q4 | 1.02 Million AUD | 0.0% |
| 2023 FY | 2.8 Million AUD | -15.86% |
| 2022 Q2 | 1.65 Million AUD | 0.0% |
| 2022 Q4 | 1.67 Million AUD | 0.0% |
| 2022 FY | 3.33 Million AUD | 149.08% |
| 2021 Q4 | 1.12 Million AUD | 0.0% |
| 2021 Q2 | 214.62 Thousand AUD | 0.0% |
| 2021 FY | 1.33 Million AUD | 73.18% |
| 2020 FY | 772.84 Thousand AUD | -8.47% |
| 2020 Q4 | 652.36 Thousand AUD | 0.0% |
| 2020 Q2 | 120.47 Thousand AUD | 0.0% |
| 2019 Q2 | 218.6 Thousand AUD | 0.0% |
| 2019 FY | 844.36 Thousand AUD | 62.21% |
| 2019 Q4 | 625.76 Thousand AUD | 0.0% |
| 2018 Q4 | 295.76 Thousand AUD | 0.0% |
| 2018 Q2 | 224.76 Thousand AUD | 0.0% |
| 2018 FY | 520.52 Thousand AUD | -2.11% |
| 2017 Q2 | 320.35 Thousand AUD | 0.0% |
| 2017 FY | 531.72 Thousand AUD | -38.72% |
| 2017 Q4 | 211.37 Thousand AUD | 0.0% |
| 2016 Q2 | 587.23 Thousand AUD | 0.0% |
| 2016 FY | 867.65 Thousand AUD | -61.0% |
| 2016 Q4 | 280.41 Thousand AUD | 0.0% |
| 2015 FY | 2.22 Million AUD | 192.82% |
| 2015 Q4 | 998.71 Thousand AUD | 0.0% |
| 2015 Q2 | 1.22 Million AUD | 0.0% |
| 2014 Q4 | 39.07 Thousand AUD | 0.0% |
| 2014 Q2 | 720.61 Thousand AUD | 0.0% |
| 2014 FY | 759.68 Thousand AUD | 28643.21% |
| 2013 Q3 | 660.75 AUD | -99.93% |
| 2013 Q2 | 893.76 Thousand AUD | 73597.13% |
| 2013 FY | 2643.00 AUD | -45.52% |
| 2013 Q1 | 1212.75 AUD | 0.0% |
| 2013 Q4 | 86.62 Thousand AUD | 13010.4% |
| 2012 Q1 | 1899.75 AUD | 0.0% |
| 2012 Q4 | 1212.75 AUD | 0.0% |
| 2012 FY | 4851.00 AUD | -36.16% |
| 2012 Q2 | 1212.75 AUD | -36.16% |
| 2012 Q3 | 1212.75 AUD | 0.0% |
| 2011 Q4 | 1899.75 AUD | 0.0% |
| 2011 Q1 | 1163.50 AUD | 0.0% |
| 2011 Q2 | 1899.75 AUD | 63.28% |
| 2011 Q3 | 1899.75 AUD | 0.0% |
| 2011 FY | 7599.00 AUD | 63.28% |
| 2010 Q3 | 1163.50 AUD | 0.0% |
| 2010 FY | 4654.00 AUD | 24.61% |
| 2010 Q1 | 933.75 AUD | 0.0% |
| 2010 Q2 | 1163.50 AUD | 24.61% |
| 2010 Q4 | 1163.50 AUD | 0.0% |
| 2009 Q1 | - AUD | 0.0% |
| 2009 FY | 3735.00 AUD | 0.0% |
| 2009 Q4 | 933.75 AUD | 0.0% |
| 2009 Q2 | 933.75 AUD | 0.0% |
| 2009 Q3 | 933.75 AUD | 0.0% |
| 2008 FY | - AUD | 0.0% |
| 2008 Q1 | - AUD | 0.0% |
| 2008 Q3 | - AUD | 0.0% |
| 2008 Q2 | - AUD | 0.0% |
| 2008 Q4 | - AUD | 0.0% |
| 2007 FY | - AUD | 0.0% |
| 2007 Q4 | - AUD | 0.0% |
| 2007 Q3 | - AUD | 0.0% |
| 2007 Q2 | - AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 50.94 Million AUD | 97.263% |
| Anatara Lifesciences Ltd | -748.91 Thousand AUD | 286.159% |
| Zelira Therapeutics Limited | 10.28 Thousand AUD | -13456.622% |
| Biome Australia Limited | 7.66 Million AUD | 81.822% |
| Orthocell Limited | 3.68 Million AUD | 62.202% |
| Imugene Limited | -5.83 Million AUD | 123.873% |
| Noxopharm Limited | -534.81 Thousand AUD | 360.683% |
| PYC Therapeutics Limited | 22.05 Million AUD | 93.68% |
| Chimeric Therapeutics Limited | 7.45 Million AUD | 81.296% |
| Prescient Therapeutics Limited | 3.71 Million AUD | 62.445% |
| Proteomics International Laboratories Limited | -1.12 Million AUD | 224.125% |
| Cynata Therapeutics Limited | 2.31 Million AUD | 39.794% |
| CSL Limited | 15.28 Billion AUD | 99.991% |
| Arovella Therapeutics Limited | -25.97 Thousand AUD | 5466.5% |
| Bio-Gene Technology Limited | -301.44 Thousand AUD | 562.487% |
| Clinuvel Pharmaceuticals Limited | 78.09 Million AUD | 98.215% |
| Starpharma Holdings Limited | 7.65 Million AUD | 81.792% |
| Nanollose Limited | -348.95 Thousand AUD | 499.529% |
| Memphasys Limited | 1606.00 AUD | -86709.651% |
| Invex Therapeutics Ltd | 1.21 Million AUD | -15.006% |
| NeuroScientific Biopharmaceuticals Limited | -91.33 Thousand AUD | 1626.395% |
| Amplia Therapeutics Limited | 4.01 Million AUD | 65.239% |
| Botanix Pharmaceuticals Limited | -6.55 Million AUD | 121.28% |
| Island Pharmaceuticals Limited | 1.25 Million AUD | -11.393% |
| Race Oncology Limited | 1.38 Million AUD | -0.306% |
| Nyrada Inc. | -5164.07 AUD | 27097.368% |
| Telix Pharmaceuticals Limited | 308.5 Million AUD | 99.548% |
| Dimerix Limited | 583.47 Thousand AUD | -138.94% |
| PharmAust Limited | -1641.00 AUD | 85058.135% |
| Immutep Limited | 1.44 Million AUD | 3.445% |
| Clarity Pharmaceuticals Ltd | 11.5 Million AUD | 87.884% |
| Alterity Therapeutics Limited | 3.8 Million AUD | 63.36% |
| BTC Health Limited | 16.36 Thousand AUD | -8421.779% |
| Acrux Limited | -1.28 Million AUD | 208.58% |
| Neuren Pharmaceuticals Limited | 205.17 Million AUD | 99.32% |
| Biotron Limited | -40.49 Thousand AUD | 3542.548% |
| Tissue Repair Ltd | 150.51 Thousand AUD | -826.286% |
| AdAlta Limited | 1.5 Million AUD | 7.544% |
| Radiopharm Theranostics Limited | -21.3 Million AUD | 106.543% |
| Hexima Limited | - AUD | -Infinity% |
| AnteoTech Limited | 460.39 Thousand AUD | -202.818% |
| Paradigm Biopharmaceuticals Limited | 56.81 Thousand AUD | -2353.994% |
| Recce Pharmaceuticals Ltd | -366.76 Thousand AUD | 480.121% |
| Avecho Biotechnology Limited | -43.79 Thousand AUD | 3283.384% |
| Actinogen Medical Limited | 9.93 Million AUD | 85.962% |
| Immuron Limited | 3.33 Million AUD | 58.219% |
| Argenica Therapeutics Limited | 2.59 Million AUD | 46.336% |